Within a phase 1 trial in pediatric and young adult patients (n = 15) with relapsed and refractory B-ALL, CAR-T cells with a bicistronic γ-retroviral vector that encodes both CD19 and CD22 CAR has also proven efficacious resulting in a remission rate of 86% [80]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.